Biotechnology

Bioxcel Therap

Bioxcel Therap released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 98K (forecast USD 216.67K), actual EPS USD -2.1774 (forecast USD -1.34)

Bioxcel Therap released FY2025 9 Months Earnings on November 12 (EST), actual revenue USD 386K, actual EPS USD -6.1244

Selvaraju focuses on healthcare stocks such as Bioxcel Therapeutics

BioXcel Therapeutics Announces Positive Results for BXCL501 Phase 3 Trial

BioXcel Therapeutics to Announce Preliminary Results of Serenity Phase 3 Safety Trial

BioXcel Therapeutics Inc. Launches ATM Program to Sell Up to $80 Million in Common Stock

BioXcel Therapeutics Inc. (BTAI) Will Release Preliminary Trial Results of Its Main Drug IGALMI

Bioxcel Therap released FY2025 Q2 earnings on August 12 EST, actual revenue USD 120 K (forecast USD 212.5 K), actual EPS USD -2.45 (forecast USD -1.8575)

Bioxcel Therap released FY2025 Semi-Annual earnings on August 12 (EST), actual revenue USD 288 K, actual EPS USD -4.1659

BioXcel Therapeutics obtains patent for treating schizophrenia

BioXcel Therapeutics Inc Receives Positive Recommendation to Continue SERENITY at Home Trial

BioXcel Therapeutics Approved by DSMB to Continue SERENITY Home Phase 3 Trial

Bioxcel Therap released FY2025 Q1 earnings on May 12 (EST), actual revenue USD 168K (forecast USD 350K), actual EPS USD -1.5006 (forecast USD -3.04)

BioXcel Therapeutics Inc Reports Q1 2025 EPS Loss

BioXcel Therapeutics Inc. may offer and sell up to $8.1 million of common stock through Canaccord

Bioxcel Therap released FY2024 annual earnings on March 27 (EST), actual revenue 2.266 M USD (forecast 2.844 M USD), actual EPS -23.5104 USD (forecast -28.7738 USD)

Bioxcel Therap released FY2024 Q4 earnings on March 27 (EST), actual revenue 366 K USD (forecast 718.26 K USD), actual EPS -3.5732 USD (forecast -6.9436 USD)

BioXcel Therapeutics Inc Reports Quarterly Financial Results with Adjusted Loss Per Share of $3.57

BioXcel Therapeutics Expects to Release Key Data for IGALMI Label Expansion in Second Half of 2025

BioXcel Therapeutics Completes 33% Enrollment in Serenity Phase 3 Safety Trial

Intelligent Bio Solutions

Anghami

UTime

ESH ACQUISITION CORP COM USD0.0001 CL A (S/R 13/06/2028)

Northann

FG MERGER II CORP COM USD0.0001 11/02/2030 (SUBS/RTS)

ESH Acquisition

INFLECTION POINT ACQUISITION CORP V COM USD0.0001 CL A (SUB/RIGHST)

RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT)

Datavault AI

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Bioxcel Therap(BTAI.US)